Research programme: hepatitis C virus infection therapies - iTherX

Drug Profile

Research programme: hepatitis C virus infection therapies - iTherX

Alternative Names: Hepatitis C ribozyme gene therapy - Immusol/Novartis; ITX 4520; ITX 7650; PCDHB

Latest Information Update: 22 Oct 2010

Price : $50

At a glance

  • Originator Immusol
  • Developer iTherX Pharmaceuticals
  • Class Antibodies; Small molecules
  • Mechanism of Action Hepatitis C virus envelope protein inhibitors; Membrane protein inhibitors; SCARB1 protein antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 22 Oct 2010 Preclinical development is ongoing USA
  • 24 Aug 2007 This programme is still in active development
  • 31 Dec 2004 Immusol and Novartis are collaborating on the development of therapies for the treatment of hepatitis C
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top